Company press releases
| Released | Company | Title | Industry | Topic |
|---|---|---|---|---|
| 30 Apr 2024 07:00 CEST |
NAVAMEDIC | Navamedic 1. kvartal 2024: Vellykket produktlansering og jevn fremgang i driften | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 30 Apr 2024 07:00 CEST |
NAVAMEDIC | Navamedic Q1 2024: Successful product launch and steady operational progress | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
| 23 Apr 2024 14:30 CEST |
NAVAMEDIC | Navamedic ASA: Invitation to 2024 1st quarter presentation | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 05 Apr 2024 13:11 CEST |
NAVAMEDIC | NOTIFICATION OF MAJOR HOLDINGS | 20103015 Pharmaceuticals | Major shareholding notifications |
| 02 Apr 2024 14:38 CEST |
NAVAMEDIC | Navamedic ASA - Registration of share capital increase | 20103015 Pharmaceuticals | Kapital- og stemmerettsendringer |
| 21 Mar 2024 13:20 CET |
NAVAMEDIC | Disclosure in NAVAMEDIC ASA | 20103015 Pharmaceuticals | Major shareholding notifications |
| 18 Mar 2024 13:38 CET |
NAVAMEDIC | Major shareholder disclosure in Navamedic ASA | 20103015 Pharmaceuticals | Major shareholding notifications |
| 15 Mar 2024 13:30 CET |
NAVAMEDIC | Navamedic ASA - Mandatory notification of trade by primary insider | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
| 15 Mar 2024 11:52 CET |
NAVAMEDIC | Navamedic ASA: Resolution to increase the share capital in connection with exercise of employee options | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 13 Mar 2024 10:43 CET |
NAVAMEDIC | Navamedic welcomes new shareholders | 20103015 Pharmaceuticals | Non-regulatory press releases |
| 13 Mar 2024 09:04 CET |
NAVAMEDIC | Navamedic ASA – Notification of Major Holdings | 20103015 Pharmaceuticals | Major shareholding notifications |
| 12 Mar 2024 22:10 CET |
NAVAMEDIC | Navamedic ASA: Notification of major shareholding and mandatory notification of trade | 20103015 Pharmaceuticals | Major shareholding notifications |
| 12 Mar 2024 16:36 CET |
NAVAMEDIC | Contemplated block sale of existing shares in Navamedic ASA | 20103015 Pharmaceuticals | Announcement from other participants |
| 22 Feb 2024 19:31 CET |
NAVAMEDIC | Navamedic ASA: Mandatory notification of trade | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
| 20 Feb 2024 16:14 CET |
NAVAMEDIC | Navamedic ASA: Notification of major shareholding and mandatory notification of trade | 20103015 Pharmaceuticals | Flagging |
| 15 Feb 2024 08:00 CET |
NAVAMEDIC | Navamedic i Q4 og 2023: Et år preget av nye rekorder, oppkjøp og avtaler som vil gi videre vekst | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 15 Feb 2024 08:00 CET |
NAVAMEDIC | Navamedic Q4 and full year 2023: A year marked by new records and transformative growth initiatives | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
| 13 Feb 2024 08:00 CET |
NAVAMEDIC | Navamedic ASA: Invitation to 2023 4th quarter presentation | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 12 Feb 2024 09:00 CET |
NAVAMEDIC | Navamedic ASA launches Eroxon® | 20103015 Pharmaceuticals | Non-regulatory press releases |
| 21 Dec 2023 17:20 CET |
NAVAMEDIC | Navamedic ASA: Renewed contract signed with Vitaflo International Limited | 20103015 Pharmaceuticals | Non-regulatory press releases |
| 15 Dec 2023 15:37 CET |
NAVAMEDIC | Financial calendar | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 15 Dec 2023 07:00 CET |
NAVAMEDIC | Navamedic ASA: Mandatory notification of trade | 20103015 Pharmaceuticals | Meldepliktig handel for primærinnsidere |
| 13 Dec 2023 18:51 CET |
NAVAMEDIC | Navamedic and Orion Corporation sign non-binding term sheet for Flexilev® in Europe | 20103015 Pharmaceuticals | Inside information |
| 01 Nov 2023 08:00 CET |
NAVAMEDIC | Navamedic ASA: Nok et rekordkvartal med over 50 prosent vekst | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 01 Nov 2023 08:00 CET |
NAVAMEDIC | Navamedic ASA: Record high quarter with above 50 percent growth | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
| 27 Oct 2023 11:13 CEST |
NAVAMEDIC | Navamedic ASA: Invitation to 2023 3rd quarter presentation | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 30 Aug 2023 13:02 CEST |
NAVAMEDIC | Navamedic ASA - Registration of share capital increase | 20103015 Pharmaceuticals | Total number of voting rights and capital |
| 18 Aug 2023 12:31 CEST |
NAVAMEDIC | Navamedic ASA - Mandatory notification of trade by primary insider | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
| 18 Aug 2023 11:56 CEST |
NAVAMEDIC | NAVAMEDIC ASA: Resolution to increase the share capital in connection with exercise of employee options | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 11 Aug 2023 08:00 CEST |
NAVAMEDIC | Navamedic ASA: Significant growth across the business | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
| 11 Aug 2023 08:00 CEST |
NAVAMEDIC | Navamedic ASA: Betydelig vekst på tvers av virksomheten | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 07 Aug 2023 12:24 CEST |
NAVAMEDIC | Navamedic ASA: Invitation to 2023 2nd quarter presentation | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 22 Jun 2023 14:37 CEST |
NAVAMEDIC | Report of changes in shareholdings, Navamedic ASA | 20103015 Pharmaceuticals | Major shareholding notifications |
| 01 Jun 2023 11:35 CEST |
NAVAMEDIC | Navamedic ASA: Minutes of Annual General Meeting | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 31 May 2023 14:16 CEST |
NAVAMEDIC | Updated recommendation by the nomination committee of Navamedic ASA | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 26 May 2023 08:00 CEST |
NAVAMEDIC | Navamedic to own a total of 96.33 per cent of shares in Sensidose following closing of public offer | 20103015 Pharmaceuticals | Inside information |
| 11 May 2023 12:00 CEST |
NAVAMEDIC | Navamedic ASA: Notice of Annual General Meeting | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 11 May 2023 08:00 CEST |
NAVAMEDIC | Navamedic ASA Q1 2023: Nok et sterkt kvartal | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 11 May 2023 08:00 CEST |
NAVAMEDIC | Navamedic ASA Q1 2023: Another strong quarter | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
| 10 May 2023 09:00 CEST |
NAVAMEDIC | Navamedic increases the consideration to SEK 8.50 in cash per share in its unconditional public offer and convenes an extraordinary general meeting of Sensidose Aktiebolag | 20103015 Pharmaceuticals | Inside information |
| 08 May 2023 10:42 CEST |
NAVAMEDIC | Navamedic ASA: Invitation to 2023 1st quarter presentation | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 28 Apr 2023 13:21 CEST |
NAVAMEDIC | Navamedic ASA: Annual Report for 2022 | 20103015 Pharmaceuticals | Annual financial and audit Reports |
| 22 Apr 2023 13:10 CEST |
NAVAMEDIC | Navamedic ASA: Amended cash offer to acquire Sensidose AB and acquisition of shares in Sensidose AB | 20103015 Pharmaceuticals | Inside information |
| 29 Mar 2023 07:31 CEST |
NAVAMEDIC | Navamedic ASA: Recommended cash offer to acquire Sensidose for approximately SEK 75 million | 20103015 Pharmaceuticals | Inside information |